System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 26 citations

PubMed: 36768852 DOI: 10.3390/ijms24032532

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.

Int J Mol Sci 24(3)

Authors: Cosmas O Okoro, Toluwase Hezekiah Fatoki

Affiliations

  • Department of Chemistry, Tennessee State University, Boswell Science Complex, Nashville, TN 37209-1561, USA.

Abstract

Several reviews of inhibitors of topoisomerase II have been published, covering research before 2018. Therefore, this review is focused primarily on more recent publications with relevant points from the earlier literature. Topoisomerase II is an established target for anticancer drugs, which are further subdivided into poisons and catalytic inhibitors. While most of the topoisomerase II-based drugs in clinical use are mostly topoisomerase II poisons, their mechanism of action has posed severe concern due to DNA damaging potential, including the development of multi-drug resistance. As a result, we are beginning to see a gradual paradigm shift towards non-DNA damaging agents, such as the lesser studied topoisomerase II catalytic inhibitors. In addition, this review describes some novel selective catalytic topoisomerase II inhibitors. The ultimate goal is to bring researchers up to speed by curating and delineating new scaffolds as the leads for the optimization and development of new potent, safe, and selective agents for the treatment of cancer.

MeSH

Poisons, Pharmaceutical Preparations, Neoplasms, Antineoplastic Agents, Research, Dna Topoisomerases, Type Ii, Topoisomerase Ii Inhibitors

Cited by